Brolucizumab ophthalmic

Generic name: Brolucizumab Ophthalmic
Brand names: Beovu
Dosage form: intravitreal solution (dbll 6 mg/0.05 mL)
Drug class: Anti-angiogenic ophthalmic agents

Usage of Brolucizumab ophthalmic

Brolucizumab is made from a human antibody fragment. It works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye). In people with certain types of eye disorders, new blood vessels grow under the retina where they leak blood and fluid.

Brolucizumab ophthalmic (for the eyes) is used to treat the "wet form" of age-related macular degeneration.

Brolucizumab ophthalmic may also be used for purposes not listed in this medication guide.

Brolucizumab ophthalmic side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Brolucizumab ophthalmic may cause serious side effects. Call your doctor at once if you have:

eye pain or redness, swelling around your eyes;

discharge or bleeding from the eye;

seeing "floaters" in your vision;

increased sensitivity to light;

decreased vision, tunnel vision, or seeing halos around lights; or

sudden numbness or weakness, problems with speech or balance.

Common side effects of brolucizumab ophthalmic may include:

blurred vision, hazy vision;

increased sensitivity to light;

eye pain; or

seeing floaters.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Brolucizumab ophthalmic

You should not use brolucizumab if you are allergic to it, or if you have:

inflammation inside your eye; or

an infection in or around your eye.

Tell your doctor if you have ever had:

glaucoma;

cataracts; or

a stroke.

Do not use brolucizumab if you are pregnant. It could harm the unborn baby or cause birth defects. Use effective birth control to prevent pregnancy while you are receiving brolucizumab ophthalmic and for at least 1 month after your last dose.

Do not breastfeed while receiving this medicine, and for at least 1 month after your last dose.

Relate drugs

How to use Brolucizumab ophthalmic

Usual Adult Dose for Macular Degeneration:

Initial dose: 6 mg by intravitreal injection once a month for the first 3 doses Maintenance dose: 6 mg by intravitreal injection once every 8 to 12 weeks Comments:-This drug should be administered by a qualified physician.-Once monthly injections should be administered approximately every 25 to 31 days. -In clinical trials, the maintenance dosing interval was guided by visual and anatomical measures of disease activity; the utility of these measures has not been established. Use: For the treatment of neovascular (wet) age-related macular degeneration (AMD).

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

What other drugs will affect Brolucizumab ophthalmic

Medicine used in the eyes is not likely to be affected by other drugs you use. But many drugs can interact with each other. Tell each of your healthcare providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.

Popular FAQ

Beovu (brolucizumab-dbll) is used to treat wet AMD (age-related macular degeneration) in adults. Two trials (HAWK and Harrier) have reported the benefits with Beovu are similar to those seen with Eylea. Improvements in visual acuity (the ability to see more clearly) started after the first injection of Beovu and were noticeable within 4 weeks, reached their maximum at 48 weeks, and persisted for at least 2 years (the length of the trial). Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.